Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00237718 · ClinicalTrials.gov registry record · Phase 2
Provision of Antioxidant Therapy in Hemodialysis (PATH) Study
A Phase 2 study, sponsored by Vanderbilt University.
- Completed
- Registry status
- Phase 2
- Development phase
- 385
- Enrollment target
NCT00237718 is a Phase 2 study that has completed, run by Vanderbilt University. The registered enrollment target is 385 participants.
The verdict
NCT00237718, a Phase 2 study, has completed, sponsored by Vanderbilt University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 385 participants
- Enrollment target
Study Summary
Studies have shown that end stage renal disease (ESRD) patients have higher levels of blood markers which their body makes in response to increased stress and injury. An increase in these markers have been shown to be related to cardiovascular disease and death in ESRD patients. This study will examine whether antioxidant therapy (Vitamin E and alpha lipoic acid) may decrease these markers.
Interventions
- DRUG Placebo
- DRUG Alpha, gamma, beta, and delta (mixed) tocopherols
- DRUG Alpha lipoic acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 385 participants |
| Start Date | 2006-04 |
| Est. Completion | 2010-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00237718
The ClinicalTrials.gov registry entry for NCT00237718 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 385 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt University, which has 430 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00237718 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00237718 about?
NCT00237718 is a clinical study titled "Provision of Antioxidant Therapy in Hemodialysis (PATH) Study". Studies have shown that end stage renal disease (ESRD) patients have higher levels of blood markers which their body makes in response to increased stress and injury. An increase in these markers have been shown to be related to cardiovascular disease and death in ESRD patients. This study will exam...
What is the current status of trial NCT00237718?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 385 participants. The study started on 2006-04. Estimated completion is 2010-09.
What interventions are being tested in trial NCT00237718?
The interventions under investigation include: Placebo (DRUG), Alpha, gamma, beta, and delta (mixed) tocopherols (DRUG), Alpha lipoic acid (DRUG).
Who is sponsoring clinical trial NCT00237718?
This trial is sponsored by Vanderbilt University, which has 430 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.